Treatment of inflammatory myopathy: Emerging therapies and therapeutic targets

Expert Review of Clinical Immunology

Volumn 11, Issue 11, 2015, Pages 1265-1275

  Moghadam Kia, Siamak ^a   Aggarwal, Rohit ^a   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

dermatomyositis; idiopathic inflammatory myopathy; myositis; polymyositis; treatment

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; SIFALIMUMAB; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DRUG TARGETING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MULTICENTER STUDY (TOPIC); MYOSITIS; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMPLICATION; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; MYELITIS; SEVERITY OF ILLNESS INDEX;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MYELITIS; SEVERITY OF ILLNESS INDEX;

EID: 84945468171     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1082908     Document Type: Review

References (101)

1. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65(2):314-24
2. Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980;92(3):365-9
3. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329(27):1993-2000
4. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326(21):1380-4
5. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84(4):231-49
6. Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007;9(4):R78
7. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S118-57
8. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52(9): 2607-15
9. Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004;43(1):49-54
10. Aggarwal R, Rider LG, Ruperto N, et al. A consensus hybrid definition using a conjoint analysis is proposed as response criteria for minimal and moderate improvement in adult polymyositis and dermatomyositis clinical trials. Arthritis and Rheum 2014;64:10 Suppl
11. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94(4):379-87
12. Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol 1999;455:349-57
13. Combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (Prometheus). Available from: https://clinicaltrials.gov/ct2/show/NCT00651040
14. Available from: http://clinicaltrials.gov/ct2/show/NCT00651040?term=methotrexate +myositis&rank=1
15. Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol 1995;1(2):99-102
16. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43(2):143-7
17. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981;24(1):45-8
18. Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47: 614-22
19. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5
20. Miller J, Walsh Y, Saminaden S, et al. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002;199(Suppl 01):S53
21. Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012;14(1):R22
22. Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 2011;30(12): 1595-601
23. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41(3):392-9
24. Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007;46(3):516-18
25. Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006;66(8):1245-7
26. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005;44(3):386-9
27. Schneider C, Gold R, Schäfers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002;25(2):286-8
28. Danieli MG, Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009;9(2): 124-7
29. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006;142(1):65-9
30. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000;27(6):1542-5
31. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009;337(5):329-35
32. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130(1):30-6
33. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010;62(10):1496-501
34. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013;40(5):640-6
35. Yamadori I, Fujita J, Kajitani H, et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol Int 2001;21:89-93
36. Katagiri A, Morimoto S, Nakiri Y, et al. Decrease in CD4+CD25+ and CD8+CD28 + T cells in interstitial pneumonitis associated with rheumatic disease. Mod Rheumatol 2008;18:562-9
37. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005;38:383-92
38. Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008;35:254-9
39. Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011;30:1021-8
40. Ingegnoli F, Lubatti C, Ingegnoli A, et al. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012;11:335-40
41. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000;27: 2855-9
42. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999;353:1762-3
43. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-46
44. Mitsui T, Kuroda Y, Ueno S, Kaji R. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg 2011;111(3): 188-94
45. Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005;23:707-10
46. Labirua-Iturburu A, Selva-O'Callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013;31:436-9
47. Cronin ME, Miller FW, Hicks JE, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989;16(9):1225-8
48. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007;46:124-30
49. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32: 1719-26
50. Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol 2003;32: 181-3
51. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46(2):467-74
52. Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011;10(3): 144-9
53. Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009;187:201-6
54. Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 2011;139:441-3
55. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78(13):1009-15
56. Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011;50(12): 2206-13
57. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010;62(9):1328-34
58. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65(7): 974-5
59. Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32(7): 1369-70
60. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006;16(5): 334-6
61. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52(2):601-7
62. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34(9): 1864-8
63. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143(6):763-7
64. Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014; 66(3):740-9
65. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-9
66. Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 2015. [Epub ahead of print]
67. Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006;33(9):1802-4
68. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70(3):427-36
69. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with antitumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50(1):10-15
70. Selva-O'Callaghan A, Martínez-Costa X, Solans-Laque R, et al. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 2004;43(9):1196-7
71. Anandacoomarasamy A, Howe G, Manolios N. Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 2005;44(4):562-3
72. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004;52(1):61-3
73. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65(9):1233-6
74. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67(12):1670-7
75. Coyle K, Pokrovnichka A, French K. A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res 2008;58:S293
76. Hengstman GJ, De Bleecker JL, Feist E. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59(3-4):159-63
77. Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol 2012;39(1):192-4
78. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010; 146(7):780-4
79. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibodypositive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010;29(5):563-6
80. Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010;37(7):1549-50
81. Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of inflammation. Scientific World Journal 2010;10:1840-53
82. Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther 2012;6:133-9
83. Acthar in treatment of refractory dermatomyositis and polymyositis. Available from: https://clinicaltrials.gov/ct2/show/NCT01906372
84. Lepidi H, Frances V, Figarella-Branger D, et al. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998;24(1): 73-9
85. Gabay C, Gay-Croisier F, Roux-Lombard P, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994;37(12):1744-51
86. Lundberg I, Ulfgren AK, Nyberg P, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40(5): 865-74
87. Narazaki M, Hagihara K, Shima Y. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011;50(7):1344-6
88. Kondo M, Murakawa Y, Matsumura T, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 2014;53(10):1907-8
89. Tocilizumab in the treatment of refractory polymyositis and dermatomyositis (TIM). Available from: https://clinicaltrials.gov/ct2/show/NCT02043548
90. Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999;155(2):453-60
91. Nagaraju K, Raben N, Villalba ML, et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999;92(2):161-9
92. Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011;78(4):431-2
93. Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012;160(3):520-2
94. Maeshima K, Kiyonaga Y, Imada C, et al. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford) 2014; 53(2):379-80
95. Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis-a case-based review. Clin Rheumatol 2015;34(3):609-12
96. Thompson B, Corris P, Miller JA, et al. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008;35(10):2080-2
97. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57(5):664-78
98. Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56(11):3784-92
99. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13(1-2):59-68
100. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60(11):3436-46
101. Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-a monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014;73(1):256-62